Arthrofibrosis Clinical Trial
— STAKOfficial title:
A Feasibility Study Considering the Use of the STAK Tool in Addition to Standard Physiotherapy Compared to Standard Physiotherapy Alone to Treat Arthrofibrosis Patients Following Total Knee Replacement
NCT number | NCT04019847 |
Other study ID # | 93160 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2, 2017 |
Est. completion date | August 19, 2019 |
Verified date | April 2020 |
Source | University Hospitals, Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A common complication following total knee replacement (TKR) is arthrofibrosis, a severe
stiffening of the knee caused by scar tissue.
The aims of this mixed methods feasibility study are to (1) record the effect of use of the
STAK Tool on knee flexion active range of movement (KROM) immediately following 8 weeks use
and 6 months following use, (2) explore patients' experiences of arthrofibrosis and use of
the STAK Tool, (3) Consider appropriate outcome measures (e.g. KROM, patient
experience/acceptability, The Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC), Oxford Knee Score (OKS) and other clinical measures and (4) design a protocol to
evaluate the effectiveness of the STAK Tool.
Status | Completed |
Enrollment | 35 |
Est. completion date | August 19, 2019 |
Est. primary completion date | August 19, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 95 Years |
Eligibility |
Inclusion Criteria: - male or female, - 18 to 95 year olds, - having received a primary total knee replacement within the last 12 months. - Following their TKR have less than 70 degrees knee flexion or have been prescribed intensive physiotherapy for their knee stiffness by their Consultant. - Between 44kg and 159kg. Exclusion Criteria: - post malignancy or knee trauma - have leaking wounds or infected joints, - have rheumatoid arthritis or osteoporosis, - have undergone long term steroid treatment or the clinician felt the patient was at risk of post-operative fracture. - Fell outside weight limits (44kg to 159kg), - Unable to give consent themselves (confusion, non-English speaking patients). |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester |
Lead Sponsor | Collaborator |
---|---|
University Hospitals, Leicester |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Semi-structured interviews | Two Semi-structured interviews conducted with intervention group to understand their experiences of having arthrofibrosis and their thoughts on the STAK Tool treatment. | Prior to and following use of the STAK Tool for 8 weeks | |
Other | Home exercise questionnaire | Questionnaire to capture patient's adherence to treatment, what this has involved, record changes in pain relief. This is a bespoke questionnaire designed by the researchers. It does not have a scale producing a final score. It provides additional information about adherence and intensity of exercise which will help us to better understand the reason for changes in range of movement |
Immediately following intervention period. | |
Other | Acceptability Questionnaire | Questionnaire regarding acceptability of the STAK Tool to patients. Questionnaire to capture patient's adherence to treatment, what this has involved, record changes in pain relief. This is a bespoke questionnaire designed by the researchers. It does not have a scale producing a final score. |
Immediately following STAK Tool intervention period. | |
Primary | Change in range of knee movement as assessed using a universal goniometer | Universal goniometer used to measure knee range of movement | Baseline, 8 weeks after intervention/control, and 6 months after intervention/control | |
Primary | Change in range of knee movement as assessed using a mobile app. | A Mobile app used to measure knee range of movement | Baseline, 8 weeks after intervention/control, and 6 months after intervention/control | |
Secondary | WOMAC Score (The Western Ontario and McMaster Universities Osteoarthritis Index) | Patient reported outcome measure relating to patient's pain, stiffness and function | Baseline, 8 weeks after intervention/control, and 6 months after intervention/control | |
Secondary | Oxford Knee Score (OKS) | Patient reported outcome measure relating to pain and function, specifically designed for total knee replacement patients. | Baseline, 8 weeks after intervention/control, and 6 months after intervention/control |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05157464 -
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
|
Phase 4 | |
Recruiting |
NCT04082533 -
Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)
|
Phase 4 | |
Active, not recruiting |
NCT03598829 -
A Prospective Clinical Trial Comparing Serum Mast Cell Tryptase (SMCT) Levels to Arthrofibrosis Rates Among Primary Total Knee Arthroplasty (TKA) Patients
|
||
Not yet recruiting |
NCT04360928 -
Knee Split Comparison After ACL Reconstruction
|
N/A |